Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Lilly Tries To Boost Evista Profile Via Comparative Trial With Fosamax

Executive Summary

Lilly will compare the osteoporosis agent Evista (raloxifene) to Merck's Fosamax (alendronate) in a head-to-head trial designed to better position the selective estrogen receptor modulator against its most successful bisphosphonate competitor.

You may also be interested in...

Wyeth Premarin Biannual Price Increases To Boost "Cheap" 60[cents] Daily Cost

Wyeth-Ayerst will adopt a biannual price increase strategy for the hormone replacement therapy Premarin, the company told analysts during its second quarter earnings call July 24.

Lilly Forteo Osteoporosis Indication Approval Recommended With Restrictions

Lilly's Forteo should be approved for treatment of osteoporosis in postmenopausal women but restricted either to high-risk patients or second-line use, FDA's Endocrinologic and Metabolic Drugs Advisory Committee recommended July 27.

Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data

Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011



Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts